Guidelines for Managing Constipation in Adults

Initial Management Approach

• The American Gastroenterological Association recommends starting with dietary modifications, including increased fluid intake and dietary fiber, along with behavioral changes such as regular exercise and scheduled toileting after meals 1, 2, 3
• Lifestyle modifications represent the initial step before pharmacological intervention, as recommended by the American Gastroenterological Association 1, 2

Pharmacological Treatment Algorithm

First-Line Therapy: Over-the-Counter Agents

• Polyethylene glycol (PEG) receives a strong recommendation as first-line therapy, starting at 17g daily, from the American Gastroenterological Association 1, 2, 4
• PEG demonstrates durable response over 6 months with moderate-quality evidence, according to the American Gastroenterological Association 5
• The American Gastroenterological Association recommends continuing PEG for 4-12 weeks before considering escalation 5, 6

Second-Line Therapy: Prescription Agents

• The American Gastroenterological Association recommends escalating to prescription agents, such as linaclotide or plecanatide, if symptoms persist after 4-12 weeks of PEG treatment 1, 2, 5
• Linaclotide 145 mcg once daily receives a strong recommendation for chronic idiopathic constipation from the American Gastroenterological Association 1, 2, 5
• Plecanatide receives a strong recommendation as an alternative secretagogue with a similar mechanism to linaclotide from the American Gastroenterological Association 1, 2, 5
• Prucalopride (serotonin type 4 agonist) receives a strong recommendation for chronic idiopathic constipation from the American Gastroenterological Association 1, 2, 5

Alternative and Rescue Therapies

• Bisacodyl or sodium picosulfate receive strong recommendations for short-term use (≤4 weeks) or rescue therapy from the American Gastroenterological Association 1, 2, 4, 5
• Senna receives a conditional recommendation with low-quality evidence from the American Gastroenterological Association 1, 2, 5
• Lactulose and magnesium oxide receive conditional recommendations from the American Gastroenterological Association 1, 2
• Lubiprostone receives a conditional recommendation from the American Gastroenterological Association 1, 2

Special Considerations

Refractory Constipation

• The American Gastroenterological Association recommends confirming adequate trial of current medications for at least 4 weeks before switching 5
• If PEG is inadequate after 4-6 weeks, the American Gastroenterological Association recommends adding or switching to a prescription secretagogue 5

Red Flags Requiring Urgent Evaluation

• The American Gastroenterological Association recommends ruling out mechanical bowel obstruction before escalating laxative therapy, particularly with prominent fecal loading on imaging 6

Important Clinical Pitfalls

• The American Gastroenterological Association recommends not continuing to escalate osmotic laxative doses indefinitely - switch to prescription agents after 4-12 weeks if inadequate response 5, 6
• The American Gastroenterological Association recommends avoiding magnesium-based laxatives in renal impairment - check creatinine clearance before prescribing 5

Cost and Accessibility Considerations

• The American Gastroenterological Association notes that PEG is inexpensive, widely available, and well-tolerated, making it the optimal first-line choice 6
• Prescription secretagogues and prokinetics are more expensive but have strong evidence for efficacy when OTC agents fail, according to the American Gastroenterological Association 5
• The 2023 AGA-ACG guidelines used the GRADE Evidence to Decision framework, which considered costs and health equity in formulating recommendations 1, 2, 7, 3

Pharmacologic Management of Chronic Constipation in Middle‑Aged Adults

First‑Line Therapy

• Polyethylene glycol (PEG) 17 g daily is strongly recommended as the optimal first‑line agent for chronic constipation, supported by moderate‑quality evidence; it provides a durable response lasting at least 6 months and is associated with common, mild adverse effects such as abdominal distension, loose stools, flatulence, and nausea. 8, 9, 10

Alternative Fiber Supplementation

• Psyllium fiber may be used as an alternative first‑line option—or in combination with PEG—for individuals with low dietary fiber intake or mild constipation; this recommendation is conditional and based on limited evidence, with flatulence being a frequent side effect. 8, 9

Second‑Line Prescription Secretagogues (after 4–12 weeks of inadequate PEG response)

• Linaclotide 145 µg once daily receives a strong recommendation for chronic idiopathic constipation; in clinical trials, 20 % of patients achieved ≥3 complete spontaneous bowel movements (CSBMs) with at least a 1‑move increase from baseline for ≥9 of 12 weeks, compared with 3–6 % on placebo. 10
• Plecanatide is strongly recommended as an alternative secretagogue with a mechanism comparable to linaclotide. 10
• Lubiprostone 24 µg twice daily carries a conditional recommendation based on lower‑quality evidence; 27.1 % of treated patients were overall responders versus 18.9 % with placebo, and spontaneous bowel movements increased within the first 24 hours in 57–63 % of patients (vs 32–37 % with placebo). 10

Prokinetic Agent

• Prucalopride 2 mg once daily is strongly recommended for chronic idiopathic constipation; it selectively stimulates 5‑HT₄ receptors to enhance colonic motility via high‑amplitude propagated contractions and is especially useful in severe motility dysfunction. 10

Rescue and Short‑Term Therapy

• Bisacodyl or sodium picosulfate are strongly recommended for short‑term (≤ 4 weeks) rescue therapy; daily use for up to 4 weeks is advised, either alone or alongside other agents. 8, 9, 10
• Senna receives a conditional recommendation with low‑quality evidence for occasional or rescue use. 10

Alternative Osmotic Laxatives

• Magnesium oxide is conditionally recommended with very low‑quality evidence; it should be avoided in patients with renal insufficiency (check renal function before prescribing) and initiated at a low dose with gradual titration as needed. 8, 9, 10
• Lactulose is conditionally recommended for patients who fail or cannot tolerate over‑the‑counter therapies; dose‑dependent bloating and flatulence are common side effects that may limit its practicality. 8, 9, 10